PDF herunterladen
Hamostaseologie 2020; 40(01): 022-030
DOI: 10.1055/s-0039-1700502
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Causes and Secondary Prevention of Acute Ischemic Stroke in Adults

Märit Jensen
1   Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
,
Götz Thomalla
1   Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
› Institutsangaben
Weitere Informationen

Publikationsverlauf

05. August 2019

10. September 2019

Publikationsdatum:
24. Oktober 2019 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Stroke still remains a major cause of death and disability worldwide. Ischemic stroke is the most common type of stroke. Causes of ischemic stroke can be classified into large-artery atherosclerosis, cardiogenic embolism, small-vessel disease, stroke of other determined etiology, and stroke of undetermined etiology. Stroke causes in adults are mainly attributable to classical cardiovascular risk factors such as hypertension, diabetes, hypercholesterolemia, and smoking. In neuroimaging, stroke subtypes can be defined according to lesion localization and distribution (territorial infarct, lacunar infarct, hemodynamic infarct), which provide information as to the underlying etiology. Acute stroke management comprises rapid neurological assessment and rapid imaging to initiate effective reperfusion treatment with intravenous thrombolysis and mechanical thrombectomy. Stroke survivors are at increased risk of recurrent stroke. Therefore, diagnosis of the underlying cause and optimal secondary prevention is of importance. Pharmacologic secondary prevention includes antithrombotic therapy with antiplatelet drugs, oral anticoagulation, and treatment of vascular risk factors. Nonpharmacologic measures of secondary prevention comprise surgical or interventional revascularization of symptomatic carotid stenosis and interventional closure of patent foramen ovale.

Zusammenfassung

Der Schlaganfall beim Erwachsenen stellt weiterhin weltweit eine der häufigsten Ursachen für Tod und Behinderung dar. Der ischämische Schlaganfall ist die häufigste Unterform und kann verschiedenen Ursachen zugeordnet werden: Makroangiopathie, kardiale Embolie, Mikroangiopathie, andere Ätiologie und unbekannte Ätiologie. Die zuvor beschriebenen Ursachen sind assoziiert mit den klassischen kardiovaskulären Risikofaktoren arterielle Hypertonie, Diabetes mellitus, Hypercholesterinämie und Rauchen. In der zerebralen Bildgebung lassen sich Schlaganfallläsionen nach Lokalisation und Verteilungen klassifizieren (territorial, lakunär, hämodynamisch), welche Hinweise auf die zugrundeliegende Ätiologie geben können. Die Akuttherapie des Schlaganfalls umfasst neben der schnellen neurologischen Untersuchung die rasche Bildgebung, um nach Ausschluss einer Blutung die weitere Akuttherapie mittels intravenöser Thrombolyse und mechanischer Rekanalisation einzuleiten. Entscheidend für die Vermeidung eines erneuten Schlaganfalls ist die umfassende Ursachendiagnostik als Basis für eine effektive Sekundärprophylaxe. Zur medikamentösen Sekundärprophylaxe zählen in erster Linie die Thrombozytenaggregationshemmung, die orale Antikoagulation und die Behandlung der kardiovaskulären Risikofaktoren. Darüber hinaus kommen als nicht-medikamentöse Maßnahmen der Sekundärprophylaxe die operative oder interventionelle Revaskularisierung einer symptomatischen Carotisstenose und der Verschluss eines persistierenden Foramen ovale in Frage.

Keywords

ischemic stroke - etiology - secondary prevention

Schlüsselwörter

ischämischer Schlaganfall - Schlaganfallursachen - Sekundärprophylaxe
 

  • References

  • 1 Collaborators GBDS. ; GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18 (05) 439-458
    CrossrefPubMedGoogle Scholar
  • 2 Wiedmann S, Heuschmann PU, Hillmann S. , et al; German Stroke Registers Study Group (ADSR). The quality of acute stroke care- an analysis of evidence-based indicators in 260 000 patients. Dtsch Arztebl Int 2014; 111 (45) 759-765
    PubMedGoogle Scholar
  • 3 Fisher CM. Lacunar strokes and infarcts: a review. Neurology 1982; 32 (08) 871-876
    CrossrefPubMedGoogle Scholar
  • 4 Barow E, Boutitie F, Cheng B. , et al; WAKE-UP Investigators. Functional outcome of intravenous thrombolysis in patients with lacunar infarcts in the WAKE-UP Trial. JAMA Neurol 2019; 76 (06) 641-649
    CrossrefPubMedGoogle Scholar
  • 5 Easton JD, Saver JL, Albers GW. , et al; American Heart Association; American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Interdisciplinary Council on Peripheral Vascular Disease. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke 2009; 40 (06) 2276-2293
    CrossrefPubMedGoogle Scholar
  • 6 Adams Jr HP, Bendixen BH, Kappelle LJ. , et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24 (01) 35-41
    CrossrefPubMedGoogle Scholar
  • 7 Lin HJ, Wolf PA, Kelly-Hayes M. , et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996; 27 (10) 1760-1764
    CrossrefPubMedGoogle Scholar
  • 8 Nah HW, Kang DW, Kwon SU, Kim JS. Diversity of single small subcortical infarctions according to infarct location and parent artery disease: analysis of indicators for small vessel disease and atherosclerosis. Stroke 2010; 41 (12) 2822-2827
    CrossrefPubMedGoogle Scholar
  • 9 Hart RG, Diener HC, Coutts SB. , et al; Cryptogenic Stroke/ESUS International Working Group. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014; 13 (04) 429-438
    CrossrefPubMedGoogle Scholar
  • 10 Thomalla G, Simonsen CZ, Boutitie F. , et al; WAKE-UP Investigators. MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med 2018; 379 (07) 611-622
    CrossrefPubMedGoogle Scholar
  • 11 Ma H, Campbell BCV, Parsons MW. , et al; EXTEND Investigators. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med 2019; 380 (19) 1795-1803
    CrossrefPubMedGoogle Scholar
  • 12 Goyal M, Menon BK, van Zwam WH. , et al; HERMES collaborators. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 2016; 387 (10029): 1723-1731
    CrossrefPubMedGoogle Scholar
  • 13 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324 (7329): 71-86
    CrossrefPubMedGoogle Scholar
  • 14 Johnson ES, Lanes SF, Wentworth III CE, Satterfield MH, Abebe BL, Dicker LW. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med 1999; 159 (11) 1248-1253
    CrossrefPubMedGoogle Scholar
  • 15 van Gijn J, Algra A, Kappelle J, Koudstaal PJ, van Latum A. ; Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325 (18) 1261-1266
    CrossrefPubMedGoogle Scholar
  • 16 Committee CS. ; CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348 (9038): 1329-1339
    CrossrefPubMedGoogle Scholar
  • 17 Johnston SC, Amarenco P, Albers GW. , et al; SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med 2016; 375 (01) 35-43
    CrossrefPubMedGoogle Scholar
  • 18 Johnston SC, Easton JD, Farrant M. , et al; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018; 379 (03) 215-225
    CrossrefPubMedGoogle Scholar
  • 19 Prasad K, Siemieniuk R, Hao Q. , et al. Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline. BMJ 2018; 363: k5130
    PubMedGoogle Scholar
  • 20 Olesen JB, Lip GY, Hansen ML. , et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011; 342: d124
    CrossrefPubMedGoogle Scholar
  • 21 Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138 (05) 1093-1100
    CrossrefPubMedGoogle Scholar
  • 22 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146 (12) 857-867
    CrossrefPubMedGoogle Scholar
  • 23 Kirchhof P, Benussi S, Kotecha D. , et al; ESC Scientific Document Group. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38) 2893-2962
    CrossrefPubMedGoogle Scholar
  • 24 Connolly SJ, Ezekowitz MD, Yusuf S. , et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
    CrossrefPubMedGoogle Scholar
  • 25 Patel MR, Mahaffey KW, Garg J. , et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
    CrossrefPubMedGoogle Scholar
  • 26 Granger CB, Alexander JH, McMurray JJ. , et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
    CrossrefPubMedGoogle Scholar
  • 27 Giugliano RP, Ruff CT, Braunwald E. , et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
    CrossrefPubMedGoogle Scholar
  • 28 Markus HS, Hayter E, Levi C, Feldman A, Venables G, Norris J. ; CADISS trial investigators. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial. Lancet Neurol 2015; 14 (04) 361-367
    CrossrefPubMedGoogle Scholar
  • 29 Menon R, Kerry S, Norris JW, Markus HS. Treatment of cervical artery dissection: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2008; 79 (10) 1122-1127
    CrossrefPubMedGoogle Scholar
  • 30 Sarikaya H, da Costa BR, Baumgartner RW. , et al. Antiplatelets versus anticoagulants for the treatment of cervical artery dissection: Bayesian meta-analysis. PLoS One 2013; 8 (09) e72697
    CrossrefPubMedGoogle Scholar
  • 31 Diener HC, Sacco RL, Easton JD. , et al; RE-SPECT ESUS Steering Committee and Investigators. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med 2019; 380 (20) 1906-1917
    CrossrefPubMedGoogle Scholar
  • 32 Harloff A, Schlachetzki F. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018; 379 (10) 986-987
    CrossrefPubMedGoogle Scholar
  • 33 Holmes Jr DR, Doshi SK, Kar S. , et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol 2015; 65 (24) 2614-2623
    CrossrefPubMedGoogle Scholar
  • 34 Group PC. ; PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358 (9287): 1033-1041
    CrossrefPubMedGoogle Scholar
  • 35 Yusuf S, Diener HC, Sacco RL. , et al; PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359 (12) 1225-1237
    CrossrefPubMedGoogle Scholar
  • 36 Schrader J, Lüders S, Kulschewski A. , et al; MOSES Study Group. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36 (06) 1218-1226
    CrossrefPubMedGoogle Scholar
  • 37 Lewington S, Whitlock G, Clarke R. , et al; Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370 (9602): 1829-1839
    CrossrefPubMedGoogle Scholar
  • 38 Amarenco P, Bogousslavsky J, Callahan III A. , et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355 (06) 549-559
    CrossrefPubMedGoogle Scholar
  • 39 Amarenco P, Goldstein LB, Szarek M. , et al; SPARCL Investigators. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007; 38 (12) 3198-3204
    CrossrefPubMedGoogle Scholar
  • 40 MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. European Carotid Surgery Trialists' Collaborative Group. Lancet 1991; 337 (8752): 1235-1243
    CrossrefPubMedGoogle Scholar
  • 41 Barnett HJM, Taylor DW, Haynes RB. , et al; North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991; 325 (07) 445-453
    CrossrefPubMedGoogle Scholar
  • 42 Brott TG, Hobson II RW, Howard G. , et al; CREST Investigators. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010; 363 (01) 11-23
    CrossrefPubMedGoogle Scholar
  • 43 Voeks JH, Howard G, Roubin GS. , et al; CREST Investigators. Age and outcomes after carotid stenting and endarterectomy: the carotid revascularization endarterectomy versus stenting trial. Stroke 2011; 42 (12) 3484-3490
    CrossrefPubMedGoogle Scholar
  • 44 Mas JL, Derumeaux G, Guillon B. , et al; CLOSE Investigators. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med 2017; 377 (11) 1011-1021
    CrossrefPubMedGoogle Scholar
  • 45 Kuijpers T, Spencer FA, Siemieniuk RAC. , et al. Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline. BMJ 2018; 362: k2515
    PubMedGoogle Scholar
  • 46 Saver JL, Carroll JD, Thaler DE. , et al; RESPECT Investigators. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med 2017; 377 (11) 1022-1032
    CrossrefPubMedGoogle Scholar
  • 47 Kasner SE, Swaminathan B, Lavados P. , et al; NAVIGATE ESUS Investigators. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. Lancet Neurol 2018; 17 (12) 1053-1060
    CrossrefPubMedGoogle Scholar
  • 48 Kernan WN, Ovbiagele B, Black HR. , et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45 (07) 2160-2236
    CrossrefPubMedGoogle Scholar
  • 49 Miyakis S, Lockshin MD, Atsumi T. , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
    CrossrefPubMedGoogle Scholar
  • 50 Bauersachs R, Schellong S, Stücker M. , et al. Therapie des Antiphospholipid-Syndroms (APS) mit DOAKs. Hamostaseologie 2019; 39 (03) 298-300
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 51 Raskob GE, van Es N, Verhamme P. , et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
    CrossrefPubMedGoogle Scholar
  • 52 Anand SS, Bosch J, Eikelboom JW. , et al; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391 (10117): 219-229
    CrossrefPubMedGoogle Scholar